4021 — Nissan Chemical Balance Sheet
0.000.00%
- ¥972bn
- ¥978bn
- ¥280bn
Annual balance sheet for Nissan Chemical, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 34,658 | 29,647 | 22,738 | 27,454 | 35,729 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 84,303 | 87,827 | 93,860 | 93,470 | 100,182 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 175,279 | 189,454 | 201,968 | 210,352 | 221,951 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 53,177 | 64,653 | 77,372 | 72,424 | 76,968 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 279,687 | 298,715 | 323,458 | 330,763 | 355,078 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 65,971 | 72,161 | 86,563 | 79,218 | 78,279 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 73,775 | 80,296 | 95,987 | 97,472 | 99,813 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 205,912 | 218,419 | 227,471 | 233,291 | 255,265 |
| Total Liabilities & Shareholders' Equity | 279,687 | 298,715 | 323,458 | 330,763 | 355,078 |
| Total Common Shares Outstanding |